Trinity Biosystems raises $7.5M bridge to treat endocrine disorders

Trinity Biosystems, maker of a drug that can treat certain endocrine disorders, has brought in $7.5 million in bridge funding from Amgen Ventures, Life Science Partners, Lilly Ventures, Sanderling Ventures and SR One, according to Dow Jones VentureWire. Based in Menlo Park, Calif., the company has raised about $33.75 million since its first round of financing in 2004.

Next Story: Penguin Computing snaps up $1.5M for Linux cluster virtualization
Previous Story: Tethys picks up $25M for diabetes diagnostic